News

Latest News

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

(DUBLIN, Ireland and FLORENCE, Italy, December 19, 2022) - Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,...
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the...
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

FLORENCE, Italy, November 30th, 2022 - The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics...
Lost childhood: a 'tight-knit' network to combat abuse and distress

Lost childhood: a 'tight-knit' network to combat abuse and distress

Rome, December 7th, 2022 – Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed...
Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Page available only in Italian language

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

NEWCASTLE UPON TYNE, UK and FLORENCE, ITALY, 2nd November 2022, QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need molecular...
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy,– November 1st, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

Page available only in Italian language

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 19, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline...
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline...
ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

ATGC Co., Ltd. (Jang, Sungsu, CEO of ATGC), a biopharmaceutical research and development company, has signed a strategic partnership, license and supply agreement with RELIFE S.r.l...
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology...
Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

NEWTON, Mass. and FLORENCE, Italy, – July 21, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

FLORENCE, 8th July 2022 – Intense emotions and immense satisfaction were in the air during the final event of the XXVI Fair Play Menarini International Award. Yesterday evening,...
NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Naarden, the Netherlands, Miami, USA and Florence, Italy; June 28, 2022 – NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of...
The XXVI Fair Play Menarini International Award opens with a press conference at CONI

The XXVI Fair Play Menarini International Award opens with a press conference at CONI

ROME – The opening whistle has blown for the XXVI Fair Play Menarini International Award. This morning, the Salone d’Onore at CONI (the Italian National Olympic Committee) in...
1345678910Last

News Archive

 

Company Profile

Download Pdf

youtube Youtube

linkedin Linkedin

Blog Item Image
MENARINI EMPLOYEES
make all the difference, every day.

We are looking for talented people: in order to achieve our mission we need energetic, versatile people with initiative and team-work skills.
Every day we do our jobs with a great sense of commitment, knowing that we are adding more value to the creation of quality drugs.

READ MORE




menarini pills of art

Menarini Pills of Art

Today, with ‘Pills of Art’, Menarini enters the city’s museums to reveal some of the curious facts on the works of the most well-known Renaissance painters. An initiative which confirms the company’s affiliation with art, a close connection which has led them to publish, each year and for more than six decades, an art monograph

Read More
Fair Play Menarini

International Fair Play Menarini Award

International Fair Play Menarini Award: the annual event which celebrates those sporting champions who have stood out in the world of sports for the brilliant results attained whilst fully respecting the rules

Read More
Menarini and Farmindustria

Menarini and Farmindustria: together we won’t rest

COVID -19 has brought many changes to our habits and our daily lives, but together we can face - and overcome - our fears. Menarini and Farmindustria, like all of us, won't rest.

Read More
EFPIA

EFPIA - We won’t rest campaign

MENARINI SUPPORTS THE EFPIA CAMPAIGN - WE WON'T REST: Disease never takes a break, so neither do we. We won't rest until people around the world see a brighter tomorrow.

Read More
newsletter

Subscribe to the newsletter

Subscribe to the newsletter to be updated on Menarini news.

Subscribe
Media Contact

Media Contact

To access the service it is necessary to declare to have read the privacy information.

Read More

The Menarini Blog

MENARINI BLOG

  • Menarini4People
  • WeAreMenarini
On Radar sets out to fight child abuse with the best experts in the field
Read More
  • Menarini4People
The Volpi Rosse Menarini are ready for a great 2023, between the A Series and the European Championship
Read More

menarini for people

Discover our responsibility projects to stand close to people

read more